Dostarlimab with chemotherapy and niraparib for treating advanced epithelial ovarian cancers – first line

Dostarlimab in combination with chemotherapy and niraparib is currently in clinical development for the first-line treatment of newly diagnosed, stage III/IV, non-mucinous advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. These cancers arise from the same type of tissue and so exhibit many similar symptoms. These include pain and swelling in the abdominal area, constipation, and a frequent urge to urinate. In advanced ovarian cancers, where the cancer has spread beyond the ovary to surrounding areas such as the pelvis and abdomen, reappearance after chemotherapy is over 70% in the first two years with few therapeutic options.